The use of concurrent long-acting injectable antipsychotic therapy with paliperidone palmitate and aripiprazole monohydrate in a patient with schizophrenia
International schizophrenia guidelines endorse seeking the patient's preference for guiding antipsychotic therapy. There exists a small niche of patients who prefer, or are required to use, long-acting injectable antipsychotic medications due to the adherence benefit. However, they may not be a...
Saved in:
Main Authors: | Christopher Evernden, BSc, BScPharm, ACPR (Author), Irene Giang, BScPharm (Author), Mariah Anderson, BScPharm (Author) |
---|---|
Format: | Book |
Published: |
American Association of Psychiatric Pharmacists,
2021-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The effects of concurrent oral paliperidone or risperidone use with paliperidone long-acting injection
by: Trevor A. Stump, PharmD, BCPP, et al.
Published: (2021) -
Effectiveness of 2-year treatment with aripiprazole long-acting injectable and comparison with paliperidone palmitate
by: Katy Mason, et al.
Published: (2021) -
Modeling the budget impact of long-acting injectable paliperidone palmitate in the treatment of schizophrenia in Japan
by: Mahlich J, et al.
Published: (2015) -
Evaluating the cost and clinical effectiveness of long-acting, injectable aripiprazole and paliperidone palmitate once a month in a real-world setting
by: Hodgson RE
Published: (2019) -
Human health benefit and burden of the schizophrenia health care pathway in Belgium: paliperidone palmitate long-acting injections
by: Sam Debaveye, et al.
Published: (2019)